Clinical trials: End Stage Renal Disease
End-stage Renal Disease, Malnutrition; Protein
Impact of IDPN on Nutrition Markers in Patients Receiving ICHD
Evaluate the impact of intradialytic parenteral nutrition (IDPN) compounded with Clinisol, Prosol, and/or Clinolipid on albumin levels and weight in patients with end-stage renal disease (ESRD) undergoing in-center hemodialysis.
- Trial name
- NCT05439174
- Testing
- Intradialytic Parenteral Nutrition
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- Patient Care America
Kidney Disease, Renal Insufficiency Chronic
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to…
- Conditions
- Kidney Disease, Renal Insufficiency Chronic, Kidney Failure, Chronic, Renal Impairment
- Trial name
- NCT07426380
- Testing
- LY3841136
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
End-Stage Renal Disease
High Flux Hemodialysis Thrice Versus Once
To investigate the influence of different dialysis frequencies on the outcome of end-stage renal disease patients undergoing chronic hemodialysis therapy.
- Trial name
- NCT00714662
- Testing
- high flux hemodialyzer (FX-60, FX-80 or FX-100)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Chronic Kidney Failure
Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction
Calcineurin inhibitors (CNI) remain the standard treatment in renal transplantation to prevent rejection. Currently the main limitation of kidney transplantation is the occurrence of chronic graft dysfunction due to the CNI…
- Trial name
- BELASBRIDGE (NCT05562869)
- Testing
- Belatacept 250 Milligram Intravenous Powder for Solution
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
End-Stage Renal Disease (ESRD)
Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy
End-stage renal disease is associated with hyperphosphatemia due to a decrease of renal phosphate excretion. This hyperphosphatemia is associated with an increase of cardiovascular risk and mortality.
- Trial name
- CIPHEMO (NCT03119818)
- Testing
- Phosphorus (31P) magnetic resonance spectroscopy, Hemodialysis
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Hospices Civils de Lyon
Chronic Kidney Disease, End Stage Renal Disease
TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment.
- Trial name
- NCT02117427
- Testing
- MDGN201 TARGTEPO
- Where
- 5 sites in Israel
- Volunteers
- 11 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Hyperphosphatemia, End Stage Renal Disease
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
The study is designed to evaluate the ability of tenapanor alone or in combination with sevelamer to achieve serum phosphorus concentration (sP) within the population reference range (sP >2.5 and ≤4.5 mg/dL) in patients with…
- Trial name
- NORMALIZE (NCT03988920)
- Testing
- Tenapanor, Sevelamer Carbonate
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Ardelyx
Renal Failure
Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis
Primary Objective: To determine the absolute bioavailability of furosemide 500 mg (Lasix® Special) oral formulation in patients with chronic renal failure undergoing peritoneal dialysis.
- Trial name
- NCT01724788
- Testing
- FUROSEMIDE, FUROSEMIDE (HOE058)
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Sanofi
Chronic Kidney Disease
Queen's University Investigation of Calcification in Chronic Kidney Disease
Kidney disease is a fundamental part of medicine because of its prominence in Western society. Common conditions such as diabetes, hypertension and kidney infections can all progress to End-Stage Renal Disease (ESRD) also known…
- Trial name
- QUICK (NCT00687661)
- Testing
- Bisphosphonate
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Queen's University
End Stage Renal Failure
Effect of Reducing Phosphorus Absorption on Cardiac Biomarkers in Hemodialysis Patients
Hyperphosphatemia and elevated cardiac biomarkers are two key characteristics of patients in end stage renal diseases(ESRD),however the majority of whom are in the absence of acute coronary syndrome(ACS).
- Trial name
- NCT01781156
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai 10th People's Hospital
Renal Failure, Chronic, End-Stage Renal Disease
PK of Serelaxin in Severe Renal Impairment and ESRD
The study is designed to evaluate the pharmacokinetics, safety and tolerability, immunogenicity and pharmacogenetics of a single dose of serelaxin/RLX030 in patients with severe renal impairment and end-stage-renal-disease (ESRD)…
- Trial name
- CRLX030A2102 (NCT01875523)
- Testing
- Serelaxin
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease
The Canadian Prevention of Renal and Cardiovascular Endpoints Trial
Advanced kidney disease with it's associated heart and blood vessel problems are becoming more frequent. These problems markedly affect length and quality of life and cost a lot to treat.
- Trial name
- CanPrevent (NCT00231803)
- Testing
- Combined CKD and CVD Prevention, Cardiovascular Disease prevention, Treatment of Chronic Kidney Disease complications
- Where
- 5 sites in Canada
- Volunteers
- 474 people
- Sponsor
- Brendan Barrett
End Stage Renal Disease
Comparison of the Clinical Performance of 3 THERANOVA 400 Dialyzer Prototypes With a High-Flux Dialyzer in Hemodialysis Mode
The study investigates the performance of a new dialyzer (Theranova 400) containing a membrane with increased pore sizes. The performance will be determined by the removal of middle molecules (with different molecular size) from…
- Trial name
- NCT02377570
- Testing
- THERANOVA 400 dialyzer prototype AA, THERANOVA 400 dialyzer prototype BB, THERNOVA 400 dialyzer prototype CC
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Vantive Health LLC
End Stage Renal Disease on Dialysis, Hemodialysis Complication
Virtual Reality Intradialysis: Last vs. First Part of the Session
The main objective of this investigation is to assess if an intradialysis virtual reality exercise program during the last two hours of the hemodialysis session results in greater hemodynamic stability than exercise performed…
- Trial name
- VRI (NCT04046042)
- Testing
- Conventional exercise, Exercise during the last two hours of the hemodialysis session
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Cardenal Herrera University
End Stage Renal Disease, Kidney Transplantation
Desensitization of Renal Transplant Candidates
Trial of the use of Myfortic to reduce anti-HLA alloantibody in patients waiting for renal transplantation.
- Trial name
- NCT00298883
- Testing
- Myfortic
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Florida
End-stage Renal Disease
Study of High Sensitive Troponin-I Level in End-stage Renal Disease Patients Receiving Hemodialysis
This study objective is to compare the high sensitive troponin-I level in end-stage renal disease patients received hemodialysis without acute cardiovascular event with healthy population.
- Trial name
- NCT02572466
- Testing
- Hemodialysis
- Where
- Thailand
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
End-stage Renal Disease, HCV Coinfection
Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease
Management of patients with hepatitis C virus (HCV) related liver disease with concomitant co-morbidity was challenging, especially in the period before the era of new direct-acting antiviral (DAA) agents.
- Trial name
- NCT03499639
- Testing
- Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet
- Where
- Egypt
- Volunteers
- 110 people
- Sponsor
- Assiut University
End Stage Renal Disease, Depression
Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis
Depression is second in frequency only to hypertension as a comorbid condition for End Stage Renal Disease (ESRD) patients. The presence of depression has been linked to lower quality of life, more medical comorbidities and…
- Trial name
- NCT00618475
- Testing
- Cognitive behavioral therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hemodialysis Patients
Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients
Atrial fibrillation is the most frequent cardiac rhythm disorder and its prognosis is essentially marked by the risk of embolic events.
- Trial name
- CARD-AXA (NCT05410275)
- Testing
- Rivaroxaban
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Tours
Hyponatremia
Regulation of Extracellular Sodium in End Stage Renal Disease Upon Volume and Electrolyte Challenges
Hyponatremia is the most common electrolyte disorder of all and can be observed in more than 30% of all patients in hospitals. Osmotic homeostasis of body fluids is essential for survival of all living creatures.
- Trial name
- RESERVE (NCT06408077)
- Testing
- Water administration, NaCl-Administration
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Cologne